Data Safety Monitoring Board (DSMB)

In Detail

A Data Safety Monitoring Board (DSMB), also called a Data Monitoring Committee (DMC), is an independent group of experts that oversees the safety and efficacy data of a clinical trial while it is still in progress. DSMB members typically include clinicians, statisticians, ethicists, and patient advocates who have no financial or professional relationship with the trial sponsor. Their primary responsibility is to protect the safety of trial participants by reviewing accumulating data at predefined intervals. The DSMB has access to unblinded data — they can see which participants are in the treatment group and which are in the control group — while the rest of the research team remains blinded. Based on their review, the DSMB can recommend continuing the trial as planned, modifying the protocol (such as changing the dose or adding safety monitoring), or stopping the trial early. A trial may be stopped early for two reasons: either the treatment is showing unacceptable safety risks (futility or harm), or the treatment is so clearly effective that it would be unethical to continue assigning participants to the control group (overwhelming benefit). DSMB oversight is required for most Phase 3 trials and is strongly recommended for Phase 2 trials. The existence of an independent DSMB is an important safeguard for participants and demonstrates that the trial has robust safety monitoring in place. The DSMB operates under a charter that defines their authority, meeting schedule, and statistical analysis plan.